A Phase II Study of Bortezomib in Combination With Dexamethasone in Patients With Relapsed Hodgkin's Lymphoma
The proteasome-inhibitor bortezomib (Velcade) shows promising activity in various human
lymphoma cell line. In addition, several studies in heavily pretreated patients with
lymphoma showed also promising results.
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Overall response rate (complete and partial responses)
University of Cologne
Germany: Federal Institute for Drugs and Medical Devices